RedHill Biopharma - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsRedHill Biopharma

RedHill Biopharma(RDHL)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Aemcolo	Rifamycin	2018-11-16	2025	—
Talicia	Amoxicillin, Omeprazole, Rifabutin	2019-11-01	2026-2042	Urinary tract infections , Sinusitis , Otitis media , Bacterial infections , Bacterial skin diseases , Soft tissue infections , Chlamydia infections , Helicobacter infections , Duodenal ulcer , Streptococcal infections , Lyme disease , Listeriosis , Human bites , Actinomycosis , Staphylococcal infections , Haemophilus infections , Nontuberculous mycobacterium infections , Gastroesophageal reflux , Infectious skin diseases , Mycoplasma pneumonia , Bronchitis , Stomach ulcer , Tonsillitis , Zollinger-ellison syndrome , Esophagitis , Protozoan infections , Pulmonary tuberculosis , Mycobacterium avium-intracellulare infection , Heartburn , Mycobacterium infections

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

,

,

,

,

,

helicobacter infections

,

,

b-cell lymphoma marginal zone

,

thrombocytopenic purpura idiopathic

,

thrombocytopenic purpura

,

healthy volunteers/patients

,

bacterial infections

,

opioid-related disorders

,

,

immunologic deficiency syndromes

,

renal insufficiency

,

,

,

pulmonary sarcoidosis

,

coronary disease

,

coronary artery disease

,

myocardial ischemia

,

,

chlamydophila infections

,

chlamydial pneumonia

,

multiple sclerosis

,

relapsing-remitting multiple sclerosis

,

,

staphylococcal infections

,

staphylococcus aureus

,

ventilator-associated pneumonia

,

,

acquired immunodeficiency syndrome

,

,

,

nontuberculous mycobacterium infections

,

,

prosthesis-related infections

,

latent tuberculosis

,

,

,

,

mycobacterium avium-intracellulare infection

,

mycobacterium infections

,

communicable diseases

,

,

,

mycobacterium avium complex

,

pulmonary tuberculosis

,

helicobacter infections

,

,

disease susceptibility

,

,

paratuberculosis

,

multiple drug resistance

,

multidrug-resistant tuberculosis

,

drug interactions

,

,

Interferon beta

alzheimer disease

,

ulcerative colitis

,

,

,

multiple sclerosis

,

,

relapsing-remitting multiple sclerosis

pancreatic neoplasms

,

,

cholangiocarcinoma

,

,

coronavirus infections

,

prostatic neoplasms

,

,

hepatocellular carcinoma

,

liver neoplasms

,

multiple myeloma

,

plasma cell neoplasms

,

,

,

large b-cell lymphoma diffuse

,

b-cell lymphoma

,

,

,

prostatic neoplasms

type 1 diabetes mellitus

,

diabetes mellitus

,

,

communicable diseases

,

community-acquired infections

,

,

,

staphylococcal infections

,

breast neoplasms

,

pancreatic neoplasms

,

,

,

myelodysplastic syndromes

,

myeloid leukemia acute

,

,

myelomonocytic leukemia chronic

,

myelomonocytic leukemia acute

,

myeloid leukemia

,

myelomonocytic leukemia juvenile

,

,

,

primary myelofibrosis

,

multiple myeloma

,

plasma cell neoplasms

irritable bowel syndrome

,

,

,

,

,

gastroenteritis

healthy volunteers/patients

1

2

>

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use